Laman UtamaPRRUF • OTCMKTS
add
Immutep Ltd
Tutup sebelumnya
$0.18
Julat tahun
$0.17 - $0.28
Permodalan pasaran
292.16J USD
Bilangan Purata
500.00
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
ASX
Berita pasaran
MarketWatch
21 jam lalu
Nvidia’s stock sees some gains melt — but an analyst glimpses big upside
ahead
2.48%
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (AUD) | Dis 2023info | Perubahan T/T |
|---|---|---|
Hasil | 1.06J | 25.23% |
Perbelanjaan pengendalian | 2.40J | 16.20% |
Pendapatan bersih | -10.61J | -2.93% |
Margin untung bersih | -1.01K | 17.80% |
Pendapatan bagi setiap syer | — | — |
EBITDA | -11.10J | -8.28% |
Kadar cukai berkesan | — | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (AUD) | Dis 2023info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 103.73J | 51.71% |
Jumlah aset | 123.79J | 43.92% |
Jumlah liabiliti | 8.15J | -12.60% |
Jumlah ekuiti | 115.64J | — |
Syer tertunggak | 1.19B | — |
Harga kepada buku | 1.83 | — |
Pulangan pada aset | -23.35% | — |
Pulangan pada modal | -24.65% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (AUD) | Dis 2023info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | -10.61J | -2.93% |
Tunai daripada operasi | -9.23J | -54.83% |
Tunai daripada pelaburan | -209.56K | -607.90% |
Tunai daripada pembiayaan | -215.93K | -278.22% |
Perubahan bersih dalam tunai | -9.84J | -69.40% |
Aliran tunai bebas | -6.90J | -2.37% |
Perihal
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Prima currently has three main products in its pipeline, all acquired with Immutep:
Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.
IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.
IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis Wikipedia
CEO
Diasaskan
2001
Tapak web
Pekerja
19
